Cover Image
市場調查報告書

藥物基因體學相關合作契約

Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016

出版商 Current Partnering, a division of Wildwood Ventures Limited 商品編碼 230291
出版日期 內容資訊 英文 120 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
藥物基因體學相關合作契約 Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016
出版日期: 2016年09月01日 內容資訊: 英文 120 Pages
簡介

本報告提供藥物基因體學相關合作契約動向分析,藥物基因體學相關的商務活動概要、驗証的主要契約內容、並參照實際的契約文件,為您概述為以下內容。

摘要整理

第1章 簡介

第2章 藥物基因體學相關交易趨勢

  • 簡介
  • 過去數年的藥物基因體學合作
  • 大型製藥公司的藥物基因體學交易活動
  • 不積極於藥物基因體學的大型製藥公司
  • 各交易型態藥物基因體學的合作
  • 不同疾病藥物基因體學合作
  • 藥物基因體學的平均交易條件

第3章 主要的藥物基因體學契約

  • 簡介
  • 金額首位契約
  • 大型製藥公司介入的主要的契約

第4章 大型製藥公司的藥理基因契約

  • 簡介
  • 大型製藥公司藥理基因合作契約的活用方法
  • 企業簡介
    • Abbott
    • AstraZeneca
    • Bayer
    • Eisai公司
    • Eli Lilly
    • GlaxoSmithKline
    • Johnson & Johnson
    • Novartis
    • Pfizer
    • Roche
    • 竹田藥品工業

第5章 藥物基因體學契約名錄

  • 簡介
  • 企業清單
  • 各開發階段
  • 不同的交易型態
  • 各治療領域

第6章 藥物基因體學合作資源中心

  • 線上
  • 活動
  • 參考文獻

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: CP2107

The ‘Global Pharmacogenomics Partnering Terms & Agreements 2010 to 2016’ report provides comprehensive understanding and unprecedented access to the pharmacogenomics partnering deals and agreements entered into by the worlds leading healthcare companies

The ‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive understanding and unprecedented access to the pharmacogenomic partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter pharmacogenomics partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors pharmacogenomics technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

This report provides details of the latest Pharmacogenomics agreements announced in the healthcare sectors.

Pharmacogenomics focusses on the influence of genetic variation on drug response in patients by correlating gene expression or single nucleotide polymorphisms with a drug's efficacy or toxicity.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases do not.

This report contains over 300 links to online copies of actual pharmacogenomics deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of Pharmacogenomics dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Pharmacogenomics dealmaking since 2010, including details of average headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading Pharmacogenomics deals since 2010. Deals are listed by headline value, signed by big pharma, most active Pharmacogenomics dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in Pharmacogenomics dealmaking with a brief summary followed by a comprehensive listing of Pharmacogenomics deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 5 provides a comprehensive and detailed review of Pharmacogenomics partnering deals signed and announced since Jan to 2010, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of Pharmacogenomics partnering deals signed and announced since Jan to 2010. The chapter is organized by specific Pharmacogenomics technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided organized by Pharmacogenomics partnering company A-Z, deal type definitions and Pharmacogenomics partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Pharmacogenomics partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Pharmacogenomics technologies and products.

Key benefits

‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of pharmacogenomics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of pharmacogenomics agreements with real life case studies
  • Detailed access to actual pharmacogenomic contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a pharmacogenomic agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to pharmacogenomic trends and structure of deals entered into by leading companies worldwide.

‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016’ includes:

  • Trends in pharmacogenomics dealmaking in the biopharma industry since 2010
  • Analysis of pharmacogenomic deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life pharmacogenomics deals
  • Access to over 300 pharmacogenomics online deal records
  • The leading pharmacogenomics deals by value since 2010
  • Most active pharmacogenomics dealmakers since 2010
  • The leading pharmacogenomics partnering resources

In ‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016’, the available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016’ report provides comprehensive access to available deals and contract documents for over 300 pharmacogenomic deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise pharmacogenomic rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Pharmacogenomics Partnering Terms and Agreements 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of pharmacogenomics deal trends since 2010
  • Access to headline, upfront, milestone and royalty data
  • Analysis of the structure of pharmacogenomics agreements with numerous real life case studies
  • Access to over 300 pharmacogenomics online deals entered into by the world's biopharma companies
  • Detailed access to actual pharmacogenomics contracts enter into by the leading fifty bigpharma companies
  • Insight into the terms included in a pharmacogenomics agreement, together with real world clause examples
  • Understand the key deal terms companies have agreed in previous deals
  • Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Pharmacogenomics dealmaking

  • 2.1. Introduction
  • 2.2. Pharmacogenomics partnering over the years
  • 2.3. Most active Pharmacogenomics dealmakers
  • 2.4. Pharmacogenomics partnering by deal type
  • 2.5. Pharmacogenomics partnering by therapy area
  • 2.6. Deal terms for Pharmacogenomics partnering
    • 2.6.1 Pharmacogenomics partnering headline values
    • 2.6.2 Pharmacogenomics deal upfront payments
    • 2.6.3 Pharmacogenomics deal milestone payments
    • 2.6.4 Pharmacogenomics royalty rates

Chapter 3 - Leading Pharmacogenomics deals

  • 3.1. Introduction
  • 3.2. Top Pharmacogenomics deals by value

Chapter 4 - Most active Pharmacogenomics dealmakers

  • 4.1. Introduction
  • 4.2. Most active Pharmacogenomics dealmakers
  • 4.3. Most active Pharmacogenomics partnering company profiles

Chapter 5 - Pharmacogenomics contracts dealmaking directory

  • 5.1. Introduction
  • 5.2. Pharmacogenomics contracts dealmaking directory

Chapter 6 - Pharmacogenomics dealmaking by technology type

Chapter 7 - Partnering resource center

  • 7.1. Online partnering
  • 7.2. Partnering events
  • 7.3. Further reading on dealmaking

Appendices

  • Appendix 1 - Pharmacogenomics deals by company A-Z
  • Appendix 2 - Pharmacogenomics deals by stage of development
  • Discovery
  • Preclinical
  • Phase I
  • Phase II
  • Phase II
  • Marketed
  • Appendix 3 - Pharmacogenomics deals by deal type
  • Asset purchase
  • Co-development
  • Collaborative R&D
  • Development
  • Distribution
  • Equity purchase
  • Evaluation
  • Grant
  • Joint venture
  • Licensing
  • Manufacturing
  • Marketing
  • Option
  • Promotion
  • Research
  • Spin out
  • Supply
  • Appendix 4 - Pharmacogenomics deals by therapy area
  • Cardiovascular
  • Genetic disorders
  • Hematology
  • Hospital care
  • Immunology
  • Infectives
  • Oncology
  • Respiratory
  • Appendix 5 -Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from Current Partnering

Table of figures

  • Figure 1: Pharmacogenomics partnering since 2010
  • Figure 2: Active Pharmacogenomics dealmaking activity- 2010 to 2016
  • Figure 3: Pharmacogenomics partnering by deal type since 2010
  • Figure 4: Pharmacogenomics partnering by disease type since 2010
  • Figure 5: Pharmacogenomics deals with a headline value
  • Figure 6: Pharmacogenomics deals with an upfront value
  • Figure 7: Pharmacogenomics deals with a milestone value
  • Figure 9: Top Pharmacogenomics deals by value since 2010
  • Figure 10: Most active Pharmacogenomics dealmakers 2010 to 2016
  • Figure 11: Online partnering resources
  • Figure 12: Forthcoming partnering events
Back to Top